Dyne Therapeutics Inc. held its annual meeting of stockholders on May 30, 2025. During the meeting, stockholders elected Edward Hurwitz and Dirk Kersten as Class II directors. Additionally, stockholders approved the compensation of the company's named executive officers on a non-binding advisory basis and recommended that future advisory votes on executive compensation be held annually. The appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was also ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.